E. Morgan

发表

Levofloxacin Inhalation Solution ( APT-1026 ) in Stable Cystic Fibrosis Patients

R. Fischer, E. Kerem, S. Aaron, 2017 .

A phase 3, multi-center, multinational, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of levofloxacin inhalation solution (APT-1026) in stable cystic fibrosis patients.

R. Fischer, E. Kerem, S. Aaron, 2016, Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society.

A phase 3, open-label, randomized trial to evaluate the safety and efficacy of levofloxacin inhalation solution (APT-1026) versus tobramycin inhalation solution in stable cystic fibrosis patients.

R. Fischer, E. Kerem, S. Aaron, 2015, Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society.

T cell receptor peptide vaccination in rheumatoid arthritis : A placebo-controlled trial using a combination of Vβ3, Vβ14, and Vβ17 peptides

T. C. Adamson, V. Strand, D. Carlo, 1998 .

Effect of Meropenem-Vaborbactam vs Piperacillin-Tazobactam on Clinical Cure or Improvement and Microbial Eradication in Complicated Urinary Tract Infection: The TANGO I Randomized Clinical Trial

K. Kaye, J. Vazquez, E. Giamarellos‐Bourboulis, 2018, JAMA.

Vaccination with a CDR2 BV6S2/6S5 peptide in adjuvant induces peptide-specific T-cell responses in patients with multiple sclerosis.

R. Moss, D. Carlo, C. Nardo, 2001, Journal of neuroscience research.

V beta 17 T cell receptor peptide vaccination in rheumatoid arthritis: results of phase I dose escalation study.

T. C. Adamson, D. Carlo, L. Moreland, 1996, The Journal of rheumatology.

Pharmacokinetics and Safety of MP-376 (Levofloxacin Inhalation Solution) in Cystic Fibrosis Subjects

D. C. Griffith, M. Dudley, P. Flume, 2011, Antimicrobial Agents and Chemotherapy.

Pharmacokinetics (PK) of aerosol MP-376 (aeroquin; levofloxacin inhalation solution) in CF patients

D. C. Griffith, M. Dudley, P. Flume, 2010 .

T cell receptor peptide vaccination in rheumatoid arthritis: a placebo-controlled trial using a combination of Vbeta3, Vbeta14, and Vbeta17 peptides.

T. C. Adamson, V. Strand, D. Carlo, 1998, Arthritis and rheumatism.

TCR Peptide Therapy in Human Autoimmune Diseases

Arthur A. Vandenbark, Dennis Bourdette, Ruth Whitham, 2001, Neurochemical Research.

Results of a Phase II Rheumatoid Arthritis Clinical Trial Using T-Cell Receptor Peptides

T. C. Adamson, V. Strand, D. Carlo, 1999 .

Discovery of a Cyclic Boronic Acid β-Lactamase Inhibitor (RPX7009) with Utility vs Class A Serine Carbapenemases.

M. Totrov, K. R. Reddy, J. Loutit, 2015, Journal of medicinal chemistry.

Phase 1 Study of the Safety, Tolerability, and Pharmacokinetics of the β-Lactamase Inhibitor Vaborbactam (RPX7009) in Healthy Adult Subjects

M. Dudley, J. Loutit, E. Morgan, 2016, Antimicrobial Agents and Chemotherapy.

401A Phase 1 Study of the Safety, Tolerability, and Pharmacokinetics of the Beta-lactamase inhibitor RPX7009 Alone, Meropenem Alone, and both in Combination (Carbavance) TID for 7 days in Healthy Adult Subjects

M. Dudley, J. Loutit, C. Rubino, 2014 .

Phase 1 Study of the Safety, Tolerability, and Pharmacokinetics of Vaborbactam and Meropenem Alone and in Combination following Single and Multiple Doses in Healthy Adult Subjects

M. Dudley, S. Bhavnani, J. Loutit, 2018, Antimicrobial Agents and Chemotherapy.

Results of a phase I clinical trial of a T-cell receptor vaccine in patients with multiple sclerosis. II. Comparative analysis of TCR utilization in CSF T-cell populations before and after vaccination with a TCRVβ6 CDR2 peptide

Larry R. Smith, D. Carlo, R. Smith, 1997, Journal of Neuroimmunology.

A synthetic androstene derivative and a natural androstene metabolite inhibit relapsing–remitting EAE

A. Vandenbark, H. Offner, A. Matejuk, 2002, Journal of Neuroimmunology.

Phase 1 Study of the Safety, Tolerability, and Pharmacokinetics of Biapenem in Healthy Adult Subjects

M. Dudley, J. Loutit, E. Morgan, 2021, Antimicrobial Agents and Chemotherapy.

Meropenem-Vaborbactam (M-V) Compared With Piperacillin-Tazobactam (P-T) in the Treatment of Adults With Complicated Urinary Tract Infections (cUTI), Including Acute Pyelonephritis (AP) in a Phase 3 Randomized, Double-Blind, Double-Dummy Trial (TANGO 1)

M. Dudley, Shu Zhang, J. Loutit, 2016 .

A synthetic androstene analogue inhibits collagen-induced arthritis in the mouse.

H. Offner, S. Subramanian, E. Morgan, 2004, Clinical immunology.

Phase 1 Study of the Safety, Tolerability, and Pharmacokinetics of the β-Lactamase Inhibitor Vaborbactam (RPX7009) in Healthy Adult Subjects

M. Dudley, J. Loutit, E. Morgan, 2016, Antimicrobial Agents and Chemotherapy.

A phase 3, open-label, randomized trial to evaluate the safety and efficacy of levofloxacin inhalation solution (APT-1026) versus tobramycin inhalation solution in stable cystic fibrosis patients.

R. Fischer, E. Kerem, S. Aaron, 2015, Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society.

218. A Phase 1 Study of the Single-Dose Safety, Tolerability, and Pharmacokinetics of the Beta-lactamase inhibitor Xeruborbactam Administered as the Isobutyryloxymethyl Oral Prodrug to Healthy Adult Subjects

M. Dudley, J. Roberts, J. Loutit, 2022, Open Forum Infectious Diseases.

216. A Phase 1 Study of the Safety, Tolerability, and Pharmacokinetics of Multiple Doses of the Beta-lactamase inhibitor Xeruborbactam Alone and in Combination Meropenem in Healthy Adult Subjects

M. Dudley, J. Roberts, J. Loutit, 2022, Open Forum Infectious Diseases.

217. A Phase 1 Study of the Safety, Tolerability, and Pharmacokinetics of Multiple Doses of the Lipopeptide QPX9003 in Healthy Adult Subjects

Y. Carmeli, M. Dudley, J. Loutit, 2022, Open Forum Infectious Diseases.